SNS01-T regulatory update

FDA granted Orphan Drug designation for Senesco's SNS01-T to treat mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL). Senesco plans to start Phase II testing of the compound for MCL...